IL-11 in Adults With Von Willebrand Disease Undergoing Surgery
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of rhIL-11 when given
subcutaneously in adults with type 1 von Willebrand disease undergoing elective surgery or
major dental procedure. Efficacy will be measured by estimated blood loss, and frequency and
severity of bleeding and transfusion requirement during and after surgery. Safety will be
measured by the frequency of adverse events, including fever, headache, fatigue, myalgias,
arthralgias, fluid retention, or edema.
Phase:
Phase 2
Details
Lead Sponsor:
Margaret Ragni University of Pittsburgh
Collaborators:
University of North Carolina Wyeth is now a wholly owned subsidiary of Pfizer